Immunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?

(1) Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor arising from the pleural surface. For relapsed MPM, there is no accepted standard of- are for subsequent treatment. Thus, we aimed to compare the efficacy of chemotherapy, targeting drugs, and immune-checkpoint inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiaotong, Lin, Lede, Zhu, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095244/
https://www.ncbi.nlm.nih.gov/pubmed/37048614
http://dx.doi.org/10.3390/jcm12072531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095244/
https://www.ncbi.nlm.nih.gov/pubmed/37048614
http://dx.doi.org/10.3390/jcm12072531

Ejemplares similares